Valeant Pharmaceuticals’ (TSX: VRX) Woes Could Make These 5 Stocks Hard To Swallow

SmallCapPower | March 22, 2016: After reporting dismal earnings and providing an outlook that was worse than analysts’ expectations, Valeant Pharmaceuticals International, Inc.’s (TSX: VRX) stock price took a 55% nosedive. Its Board has since initiated a new CEO search, and has installed activist hedge fund manager, Bill Ackman, as a board member. The negativity surrounding Valeant may have a ripple effect on its industry, which could hurt smaller players such as the ones on our list today.

Concordia Healthcare Corp. (TSX: CXR) – $38.61
Pharmaceuticals

Concordia Healthcare Corp. is a Canada-based diverse healthcare company that is focused on legacy pharmaceutical products and orphan drugs. The Company operates through three segments, which includes Legacy Pharmaceutical Division, Concordia Pharmaceuticals Inc., which consists of 23 products, including Nilandron, for the treatment of metastatic prostate cancer; Dibenzyline, for the treatment of pheochromocytoma; Lanoxin, for the treatment of mild-to-moderate heart failure and atrial fibrillation; Plaquenil, for the treatment of lupus and rheumatoid arthritis; Donnatal, for the treatment of irritable bowel syndrome, and Zonegran (zonisamide), for treatment of partial seizures in adults with epilepsy.

• Market Cap: $1,790,728,391
• 5 Day Price Change: -24%
• Average Daily Traded Value – 30 Days: $19,293,091
• Total Revenues (LTM): $319,228,937

Cardiome Pharma Corp. (TSX: COM) – $5.20
Pharmaceuticals

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company that is focused on the development and commercialization of cardiovascular therapies that improve the life and health of patients suffering from heart disease. The Company has two marketed, in-hospital, cardiology products, BRINAVESSTM and AGGRASTAT, which are commercially available in markets outside of the United States.

• Market Cap: $102,911,475
• 5 Day Price Change: -17%
• Average Daily Traded Value – 30 Days: $33,395
• Total Revenues (LTM): $27,268,776

QLT Inc. (TSX: QLT) – $2.66
Biotechnology & Medical Research

QLT Inc. (QLT) is a biotechnology company engaged in the development and commercialization of ocular products. QLT is involved in the development of QLT091001 for the treatment of Leber congenital amaurosis (LCA) and retinitis pigmentosa (RP). QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, a biochemical component of the visual retinoid cycle, and is used for the treatment of certain age-related and inherited retinal degenerative diseases.

• Market Cap: $143,695,963
• 5 Day Price Change: -13%
• Average Daily Traded Value – 30 Days: $12,833
• Total Revenues (LTM): $0

Cynapsus Therapeutics Inc. (TSX: CTH) – $16.10
Biotechnology & Medical Research

Cynapsus Therapeutics Inc. is a Canada-based clinical-stage, specialty pharmaceutical company engaged in developing a sublingual thin filmstrip to manage OFF episodes associated with Parkinson’s disease. The Company’s drug candidate is APL-130277, which is a reformulation of apomorphine. It is an approved acute drug in the United States, Europe, Japan and other countries. Cynapsus completed a CTH-105 Phase II clinical trial comprising approximately 16 people with Parkinson’s disease.

• Market Cap: $197,677,941
• 5 Day Price Change: -10%
• Average Daily Traded Value – 30 Days: $53,933
• Total Revenues (LTM): $0

Neptune Technologies & Bioressources Inc. (TSX: NTB) – $1.37
Biotechnology & Medical Research

Neptune Technologies & Bioressources Inc. is a Canada-based biotechnology company engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids (PUFAs). The Company has three operating segments: Neptune, Acasti Pharma Inc. and NeuroBioPharm Inc. The Company’s Neptune segment produces and commercializes nutraceutical products. The Company’s Acasti Pharma Inc. segment develops and commercializes medical food and pharmaceutical products for cardiovascular diseases. The Company’s NeuroBioPharm Inc. segment develops medical food and pharmaceutical products for neurological diseases. Neptune Technologies’ lead product, Neptune Krill Oil (NKO), comes in capsule form and serves as a dietary supplement to consumers.

• Market Cap (mm): $107,564,856
• 5 day Price Change: -8%
• Average Daily Traded Value – 30 Days: $30,163
• Total Revenues (LTM): $16,622,570

DISCLAIMER
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source.